Limited coverage drugs – bimekizumab

Last updated on February 5, 2024

Special Authority requests can now be submitted online. It's simple and quick!

Generic name	bimekizumab
Strength	160 mg/mL
Form	solution for subcutaneous injection in a pre-filled syringe or pre-filled autoinjector

Special Authority criteria	Approval period
Treatment of moderate to severe plaque psoriasis, according to criteria detailed in form HLTH 5380: Biologics for Moderate to Severe Psoriasis (PDF, 781KB), when prescribed by a dermatologist	First approval: 16 weeks Renewal: 1 year

Practitioner exemptions

No practitioner exemptions

Special notes

PharmaCare covers a maximum of 56 days per fill for bimekizumab (coverage limited to one 320 mg dose every 8 weeks at maintenance dosing)

Special Authority request form(s)

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Limited coverage drugs – bimekizumab

Practitioner exemptions

Special notes

Special Authority request form(s)